Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- Amgen (AMGN) has delivered robust double-digit revenue growth in recent quarters, driven by a diversified portfolio spanning general medicine, rare disease, inflammation, oncology, and biosimilars.
- Biogen (BIIB) is navigating a turnaround, with newer drugs like Skyclarys and Leqembi offsetting persistent declines in its legacy multiple sclerosis (MS) franchise.
- Amgen's market capitalization of approximately $198 billion dwarfs Biogen's roughly $30 billion, reflecting vastly different scales of operation and investor confidence.
- Both companies face pipeline risk, but Amgen's late-stage obesity candidate MariTide and cardiovascular program olpasiran represent potentially transformative opportunities, while Biogen's Alzheimer's strategy and rare disease expansion carry higher execution uncertainty.
- Amgen's broad revenue base and multiple growth drivers offer greater stability, while Biogen presents a higher-risk, higher-reward proposition centered on neuroscience innovation.
- Analyst consensus leans toward a Hold on Amgen and a more cautious outlook on Biogen, with recent downgrades reflecting concern over growth sustainability.
Introduction
Biotechnology investing demands careful evaluation of pipeline strength, commercial execution, and financial durability. AMGN and BIIB represent two distinct approaches to value creation in the biopharmaceutical sector — one built on diversification and scale, the other on neuroscience specialization. This stock comparison examines how these two industry heavyweights stack up across key dimensions including recent performance, growth catalysts, risk exposure, and market sentiment. For investors weighing large-cap biotech allocations, understanding the contrasts between Amgen's broad-based momentum and Biogen's focused turnaround effort is essential to informed decision-making in the current market environment.
Amgen Overview and Recent Performance
Amgen Inc., headquartered in Thousand Oaks, California, is one of the world's largest independent biotechnology companies, with a market capitalization approaching $198 billion. The company's portfolio spans general medicine, rare disease, inflammation, oncology, and a rapidly expanding biosimilars segment. In recent quarters, Amgen has posted impressive financial results, including 9% year-over-year revenue growth in Q1 2025, with non-GAAP earnings per share (EPS) rising 24%. Fourteen products delivered double-digit sales growth during that period, and 17 products were annualizing at over $1 billion in sales. Key growth drivers include Repatha (cholesterol-lowering), EVENITY (osteoporosis), TEZSPIRE (severe asthma), and the rare disease portfolio anchored by TEPEZZA (thyroid eye disease). The company's biosimilars business has also surged, with revenue up 35% year-over-year, supported by new U.S. launches. Amgen's stock has exhibited resilience in recent market activity, and the company has guided to 45%–46% operating margins for the current year. That said, the company has faced headwinds, including the halting of a late-stage bemarituzumab gastric cancer trial and the termination of a Phase 3 rocatinlimab eczema study, which have introduced some uncertainty into portions of its oncology and inflammation pipeline.
Biogen Overview and Recent Performance
Biogen Inc., based in Cambridge, Massachusetts, is a pioneer in neuroscience-focused biotechnology with a market capitalization of roughly $30 billion. The company has long been synonymous with multiple sclerosis (MS) treatments, including Tecfidera, Avonex, and Tysabri. However, these legacy products have faced intensifying generic competition and pricing pressure, resulting in consistent revenue erosion. In response, Biogen has pivoted toward rare disease therapies and Alzheimer's disease treatments. Recent quarterly results have shown encouraging signs: Q2 2025 revenue reached $2.65 billion, a 7% year-over-year increase, exceeding analyst expectations and prompting management to raise full-year non-GAAP EPS guidance to a range of $15.50–$16.00. The rare disease portfolio, including Skyclarys (for Friedreich's ataxia) and Spinraza, generated $543 million in Q2 sales. Meanwhile, Leqembi, Biogen's Alzheimer's drug co-developed with Eisai, posted $63 million in U.S. revenue during the same period — a fourfold annual increase. Despite these bright spots, Biogen's stock has underperformed the broader market significantly, with shares trading well below their 52-week high. A recent analyst downgrade from Truist, which cut its rating from Buy to Hold and slashed its price target, underscored persistent concerns about long-term growth prospects and the high-risk nature of Biogen's late-stage pipeline.
Trending AI Robots
In a market environment where data-driven decision-making can mean the difference between outperformance and underperformance, traders are increasingly turning to AI-powered tools for an analytical edge. Tickeron's Trending AI Robots page features a curated selection of hundreds of AI trading bots, each designed to trade thousands of different tickers across varying strategies, timeframes, and market conditions. Only the most effective and currently relevant bots earn a place in this section. These AI trading bots employ distinct trading styles — from swing trading to long-term trend following — and offer a range of performance statistics, including win rates, trade frequency, and historical return profiles. Some bots maintain win rates above 70%, while others specialize in high-volatility or defensive positioning depending on market regimes. Whether analyzing AMGN and BIIB or scanning the broader market, these tools help traders filter noise and identify statistically grounded opportunities. Explore the Trending AI Robots page to see which strategies are currently resonating with real-time market conditions.
Head-to-Head Comparison
Amgen and Biogen diverge sharply across several critical dimensions. Scale and Diversification: Amgen's product portfolio is substantially broader, with 14 products exceeding $1 billion in annualized sales spanning five therapeutic areas. Biogen remains heavily dependent on neuroscience, with its MS franchise still contributing roughly $1.1 billion per quarter despite structural decline. Growth Trajectory: Amgen has consistently posted mid-to-high single-digit revenue growth, powered by volume-driven demand across multiple franchises and a thriving biosimilars unit. Biogen's growth is more narrowly concentrated in rare disease and Alzheimer's, making it less predictable quarter to quarter. Pipeline Potential: Amgen's MariTide obesity program and olpasiran cardiovascular candidate address massive addressable markets and are in late-stage development. Biogen's pipeline, while promising — including felzartamab for kidney disease and a subcutaneous formulation of Leqembi — is viewed by some analysts as higher-risk and further from commercialization. Risk Profile: Amgen faces upcoming patent expiries on its denosumab franchise (Prolia/Xgeva) and ongoing IRS tax disputes, while Biogen contends with MS revenue erosion and the uncertain commercial trajectory of Leqembi. Market Sentiment: Amgen commands a consensus Hold rating with a price target near $357, reflecting cautious optimism. Biogen has seen more negative analyst action, with downgrades and reduced price targets reflecting skepticism about its near-term growth narrative.
Tickeron AI Verdict
Based on observable market data — including trend consistency, revenue diversification, earnings momentum, and relative stability of growth drivers — Tickeron's AI analytical framework would likely favor AMGN over BIIB in the current market environment. Amgen's broader revenue base, double-digit growth across multiple products, and clearer path to sustainable earnings expansion provide a more consistent trend profile for AI-driven models to identify and track. While Biogen's turnaround story and Alzheimer's catalyst cannot be dismissed, the company's higher volatility, concentration risk in neuroscience, and less predictable revenue trajectory introduce greater uncertainty into forward-looking assessments. This does not diminish Biogen's potential for outsized returns under favorable circumstances, but from a probabilistic standpoint that weighs trend strength and risk-adjusted positioning, Amgen appears to offer the steadier setup. As always, market conditions evolve, and AI-driven analysis continuously adapts to incoming data — making tools like Tickeron's AI robots valuable for staying aligned with shifting dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 5 bearish.
- BIIB’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.80% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +3.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.15%. For the same industry, the average monthly price growth was +4.60%, and the average quarterly price growth was +8.29%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
BIIB is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.15% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BIIB | AMGN / BIIB | |
| Capitalization | 198B | 30.4B | 651% |
| EBITDA | 16.7B | 2.7B | 619% |
| Gain YTD | 13.536 | 17.046 | 79% |
| P/E Ratio | 25.49 | 22.15 | 115% |
| Revenue | 37.2B | 9.94B | 374% |
| Total Cash | 12B | 4.28B | 280% |
| Total Debt | 57.3B | 6.56B | 873% |
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 19 | 100 | |
SMR RATING 1..100 | 12 | 79 | |
PRICE GROWTH RATING 1..100 | 27 | 12 | |
P/E GROWTH RATING 1..100 | 59 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is significantly better than the same rating for BIIB (85). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for BIIB (79). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (12) in the Biotechnology industry is in the same range as AMGN (27). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for AMGN (59). This means that BIIB’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 55% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 54% | 3 days ago 58% |
| Momentum ODDS (%) | 3 days ago 52% | 3 days ago 74% |
| MACD ODDS (%) | 3 days ago 51% | 3 days ago 72% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 58% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 61% |
| Advances ODDS (%) | 4 days ago 59% | 4 days ago 57% |
| Declines ODDS (%) | 6 days ago 51% | 11 days ago 70% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 75% |
| Aroon ODDS (%) | 3 days ago 53% | 3 days ago 52% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -1.42% | ||
| BIIB - AMGN | 62% Loosely correlated | -1.40% | ||
| BMY - AMGN | 59% Loosely correlated | +0.38% | ||
| NVS - AMGN | 58% Loosely correlated | +0.67% | ||
| GSK - AMGN | 57% Loosely correlated | -1.91% | ||
| PFE - AMGN | 52% Loosely correlated | -0.36% | ||
More | ||||
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -1.40% | ||
| AMGN - BIIB | 50% Loosely correlated | -1.42% | ||
| PFE - BIIB | 50% Loosely correlated | -0.36% | ||
| AZN - BIIB | 49% Loosely correlated | -0.23% | ||
| MRK - BIIB | 49% Loosely correlated | -0.10% | ||
| BMY - BIIB | 46% Loosely correlated | +0.38% | ||
More | ||||